Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565928 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01565928 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT01565928, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.
Interventions
- DRUG MDV3100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-01-24 |
| Est. Completion | 2018-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01565928
The ClinicalTrials.gov registry entry for NCT01565928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDV3100 is the first listed.
NCT01565928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01565928 about?
NCT01565928 is a clinical study titled "Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer". The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.
What is the current status of trial NCT01565928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2012-01-24. Estimated completion is 2018-02-26.
What interventions are being tested in trial NCT01565928?
The interventions under investigation include: MDV3100 (DRUG).
Who is sponsoring clinical trial NCT01565928?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.